Review Wednesday, September 8
All time in CET (EET = +1hr / BST = -1hr / EST = -6hr)
09:00 LSX Welcome
Josh Dance, SVP, LSX
The Nordics as an engine for new therapies and technologies in healthcare is phenomenal, with outstanding quality and quantity of research, huge numbers of patented innovations and a reputation as one of the world's leading innovation hubs.
However, does this research and innovation make it out into companies, who can then get it closer to patients, as much as it should? Are the Nordics actually punching below their weight and potential?
This webinar presents an in-depth report and analysis of the Nordic life science and healthcare space, and the drivers, trends and challenges it faces in realising its full potential.
Karsten Dalgaard, Senior Partner, McKinsey & Company
Pavel Gongora, Associate Partner, McKinsey & Company
The relatively early public listing of Nordic life science companies in their financing and clinical development is common, driven by the need for growth capital which was not always available from specialist VCs, and a strong retail investor base in the region. But with more local funds, greater international attention and investment, and a globally booming healthcare sector, the market for private growth capital has arguably never been stronger.
On the flipside, 2020 and 2021 has seen a large number of public fundraises for life science companies, particularly on the Swedish market, proving a strong interest from institutional investors and availability of capital for the right companies. A multi-stakeholder panel discusses this critical dynamic in the Nordic market.
Stephan Christgau, Managing Partner, Eir Ventures
Adam Kostyal, SVP, Nasdaq
Lena Soderstrom, Chair, InfiCure
Jonas Jendi, Investment Director & Head of Analysis, Industrifonden
Moderator: Don DeBethizy, Director, Argenx
The Nordic countries lead the way in terms of gender equality and diversity. In life sciences, the backing of female-led businesses and women in VC , this leadership role does broadly seem to translate. What is being done right in the Nordics and what can other countries learn from this relative success? How far is there still to go in creating a truly equitable life science ecosystem in the region?
Roger Franklin, Partner, Hadean Ventures
Inka Mero, Founder & Managing Partner, Voima Ventures
Petrina Knowles Gjelstrup, SVP People & Organisation, Novo Holdings & The Novo Nordisk Foundation
Ian Coyne, Consulting Partner, Coulter Partners
Jenni Nordborg, Head of the Office for Life Sciences, Government Offices Sweden
The speed and diversity of innovation in healthcare continues grow and business models continue to evolve. Alongside research institutions becoming more advanced in the way they look at translating innovation, pharma and investors are increasingly looking earlier for great science and technology and incubators and accelerators are supporting entrepreneurs and earlier stage companies more than ever before. A multi-stakeholder panel discusses translation of innovation from the Nordics, and what lessons can be learned from partnerships and how other countries and regions are trying to speed up the process of getting the latest advancements from academia to industry.
Bobby Soni, CBO, BioInnovation Institute
Richard Reschen, Associate Director Business Development, MSD
Magnus Björsne, CEO, AZ BioVentureHub
Klementina Österberg, CEO, GU Ventures
Jonathan Tobin, Investment Director, Brandon Capital Partners
Biotechnology often offers a promise of future success but knowing it can take years and needs proper planning to determine how the effort and expense will translate into returns. In this 45-minute interactive workshop, held in a Zoom breakout room, experts will explore the key considerations around biotech valuations when preparing for out-licencing deals for specific assets, considering a public listing or when raising a next round of financing.
Tobias Thornblad, CEO, MS&C Nordics
With increased capital flow, and companies looking to go further with longer term aspirations, is the pharma deal-making landscape getting tougher? With more competition than ever before, better funded companies and higher valuations, is making win-win deals harder for international pharma? Pharma BD&L heads discuss how evolving industry and investment dynamics are impacting pharma’s approach, and how Nordic innovation across the healthcare spectrum fits into their business development and deal-making strategies.
Karen McGurk, Executive Director Transactions, MSD
Miriam Frieden, VP S&E, Novo Nordisk
James Stamatis, Vice President, Head of Business Development and Acquisitions, AbbVie
Tahera Kan, VP Early Innovation Partnering, Johnson & Johnson Innovation, Johnson & Johnson
Keld Flintholm Jørgensen, EVP & CBO, Lundbeck
Moderator: Christine Lind, VP Commercial, NDA Group
Nikolaj Sørensen, CEO, Orexo
Joe Coveney, VP Corporate Services, OTC Markets Group
Adam Kostyal, SVP, Nasdaq
Marius Halvorsen, Head of Investment Banking, Arctic Securities
Moderator: Josh Dance, SVP, LSX
The Nordic ecosystem has produced world-leading medtech businesses, and innovation in the space continues apace. Sooner or later, any ambitious medtech company is going to look to the US to build a footprint and eventually commercialise their products. Early planning, securing requisite investment and an ambitious mindset with the right partners is key to realising this vision. What are the keys to securing international investment, and a successful well planned internationalisation programme?
Jonathan Gertler, Managing Director, BioVentures MedTech Funds
Stine Mølgaard, COO & Co-founder, Radiobotics
Niels Erik Holm, Executive Advisor, Reapplix
Tim Damgaard Christensen, Managing Partner - Denmark, MedTech Bridge
Moderator: John Rudy, Partner, Mintz
17:00 Video Networking Reception